MHRA shuts down illegal weight loss jab factory in record seizure

24 October 2025

UK regulators have dismantled a major illicit operation producing unlicensed weight loss medicines, following a raid on a Northampton warehouse. The Medicines and Healthcare products Regulatory Agency (MHRA) said the site marks the first illegal production facility for such products found in the country.

The raid uncovered tens of thousands of empty injector pens, raw ingredients, and more than 2,000 finished retatrutide and tirzepatide pens awaiting shipment. Officials estimated the street value of the seized products at more than £250,000 ($320,000). Around £20,000 in cash, believed to be linked to trafficking, was also recovered.

Health Secretary Wes Streeting called the seizure “a victory in the fight against shameless criminals,” warning the public not to buy medicines from unregulated sources. He said legitimate obesity treatments can be effective only when used under medical supervision.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



More ones to watch >




Today's issue

Company Spotlight



More Features in Pharmaceutical